Zinc‑Responsive Acrodermatitis Enteropathica

Overview

Acrodermatitis enteropathica (AE) is a rare, inherited disorder of zinc absorption that presents with a characteristic triad of skin lesions, alopecia, and diarrhea. When the condition improves rapidly after zinc supplementation, it is termed zinc‑responsive acrodermatitis enteropathica. The disease is caused by mutations in the SLC39A4 gene, which encodes the ZIP4 zinc‑transport protein located in the intestinal epithelium. Because zinc is essential for over 300 enzymatic reactions, a deficiency can affect many organ systems.

Who it affects: The classic form is autosomal recessive, so it most often appears in infants after weaning from breast‑milk (when dietary zinc becomes the sole source). However, acquired zinc deficiency can mimic AE in adults with malabsorption, chronic diarrhea, or prolonged parenteral nutrition. Worldwide prevalence is estimated at < 1 per 500,000 live births, but exact numbers are uncertain due to under‑diagnosis (NIH, 2020).

Symptoms

The clinical picture can vary with age and severity, but most patients exhibit the following:

• Dermatologic lesions – sharply demarcated, erythematous, scaly plaques that become crusted or vesiculobullous. Typical locations:
  • Perioral and perianal skin
  • Extremities (especially acral areas – hands, feet, elbows, knees)
  • Scalp and neck
• Alopecia – diffuse thinning or patchy hair loss affecting scalp, eyebrows, and eyelashes.
• Gastrointestinal disturbances – chronic watery diarrhea, abdominal pain, and poor weight gain.
• Growth failure – failure to thrive in infants; delayed height and weight percentiles.
• Oral manifestations – glossitis, angular cheilitis, and ulcerations of the oral mucosa.
• Neurologic signs – irritability, lethargy, and in severe cases, seizures or peripheral neuropathy.
• Immune dysfunction – increased susceptibility to infections, especially respiratory and gastrointestinal.
• Laboratory abnormalities – low serum zinc (<70 µg/dL) and low alkaline phosphatase (a zinc‑dependent enzyme).

Causes and Risk Factors

Genetic cause

The disease results from loss‑of‑function mutations in SLC39A4 (ZIP4). Over 30 pathogenic variants have been identified (OMIM). The defective transporter impairs active zinc uptake in the duodenum and jejunum, leading to systemic deficiency despite normal dietary intake.

Acquired (secondary) zinc deficiency

Although not true “genetic” AE, many adults develop a zinc‑responsive picture that mimics the inherited form. Common risk factors include:

1. Chronic malabsorption syndromes (celiac disease, Crohn’s disease, short‑bowel syndrome).
2. Prolonged parenteral nutrition without adequate zinc supplementation.
3. Excessive losses from severe burns, dialysis, or chronic diarrhea.
4. High phytate diets (e.g., unrefined grains, legumes) that bind zinc and reduce absorption.
5. Use of zinc‑chelating medications (e.g., penicillamine, tetracyclines).

Who is at higher risk?

• Infants of consanguineous parents (higher chance of autosomal recessive inheritance).
• Individuals with a family history of AE.
• Patients with gastrointestinal surgeries that bypass the duodenum.
• People on long‑term total parenteral nutrition (TPN) without zinc.

Diagnosis

Diagnosis is a combination of clinical suspicion, laboratory testing, and genetic confirmation.

Step‑by‑step diagnostic approach

1. Clinical evaluation – detailed history (onset after weaning, family history, diet) and physical exam focusing on the classic skin distribution.
2. Serum zinc level – measured by atomic absorption spectroscopy or inductively coupled plasma mass spectrometry. Levels <70 µg/dL are suggestive, but normal levels do not exclude the disease if the patient is on zinc supplements.
3. Alkaline phosphatase – low activity (<30 U/L) supports zinc deficiency because the enzyme is zinc‑dependent.
4. Skin biopsy (optional) – shows epidermal hyperplasia, parakeratosis, and a mixed inflammatory infiltrate; useful to rule out other dermatoses.
5. Genetic testing – sequencing of SLC39A4 confirms the diagnosis in >95 % of suspected cases (Mayo Clinic, 2021).
6. Therapeutic trial – rapid improvement (within 48–72 h) after oral zinc supplementation is both diagnostic and therapeutic.

Differential diagnosis

• Acrodermatitis continua of Hallopeau
• Psoriasis
• Atopic dermatitis
• Contact dermatitis
• Other micronutrient deficiencies (e.g., biotin, essential fatty acids)

Treatment Options

Because the underlying problem is zinc malabsorption, lifelong zinc supplementation is the cornerstone of therapy.

Pharmacologic therapy

• Oral zinc sulfate – most commonly used; initial dose for infants is 1 mg/kg elemental zinc 3–4 times daily (≈3 mg/kg/day). For older children and adults, 50–150 mg elemental zinc per day divided doses is typical (CDC, 2022).
• Zinc gluconate or zinc acetate – alternative salts with better gastrointestinal tolerance for some patients.
• Intravenous zinc – reserved for severe malabsorption, acute crises, or when oral intake is impossible.
• Adjunctive nutrients – supplementation with copper (to prevent copper deficiency from high zinc intake) and a balanced multivitamin may be recommended.

Monitoring and dose adjustment

1. Check serum zinc and copper levels every 3–6 months during the first year, then annually.
2. Assess growth parameters, skin lesion severity, and neuro‑developmental milestones.
3. Adjust dose based on clinical response and laboratory values; overtreatment can cause copper deficiency, anemia, and neutropenia.

Lifestyle and supportive measures

• Maintain a diet low in phytates (limit unrefined grains, legumes, and soy unless properly prepared).
• Encourage adequate protein intake, as zinc binds to amino acids for absorption.
• Use gentle skin care: fragrance‑free moisturizers, mild soap, and avoid scratching.
• Prompt treatment of secondary infections with topical or systemic antibiotics as needed.

Living with Zinc‑Responsive Acrodermatitis Enteropathica

With proper management, most patients lead normal lives. Below are practical tips for daily living.

Medication adherence

• Set alarms or use a pill‑box to ensure multiple daily doses are taken.
• Keep a travel‑size supply of zinc tablets for trips or emergencies.
• Discuss any side‑effects (nausea, metallic taste) with a clinician; switching salts often helps.

Nutrition

• Include zinc‑rich foods such as lean meat, shellfish, pumpkin seeds, and fortified cereals, but do not rely on diet alone.
• Soak, sprout, or ferment beans and grains to reduce phytate content.
• Consider a registered dietitian experienced in micronutrient disorders.

Skin care routine

1. Wash affected areas with lukewarm water and a mild, fragrance‑free cleanser.
2. Pat dry; apply a barrier ointment (e.g., petroleum jelly) to prevent moisture loss.
3. Use a prescribed topical corticosteroid only during flare‑ups and under physician guidance.

School and work considerations

• Provide the school nurse or employer with a written medication plan.
• Explain that zinc supplementation is not a “performance‑enhancing” drug but a medical necessity.
• Arrange for flexible break times to take medication with food.

Psychosocial support

Living with a visible skin condition can affect self‑esteem. Support groups (e.g., Rare Disease Foundation forums) and counseling can be valuable. Many families report that early diagnosis and rapid symptom control improve quality of life dramatically.

Prevention

Because the inherited form cannot be prevented, the focus is on early detection and minimizing secondary zinc deficiency.

• Newborn screening – not routinely performed, but families with known carrier status can request genetic counseling and early testing.
• Maternal nutrition – adequate zinc intake during pregnancy (11 mg/day) supports fetal stores (WHO, 2020).
• Breast‑feeding – breast‑milk provides highly bioavailable zinc; exclusive breastfeeding for the first 4–6 months can delay symptom onset.
• Monitoring high‑risk patients – children with chronic diarrhea, inflammatory bowel disease, or on TPN should have periodic zinc level checks.

Complications

If zinc deficiency remains untreated, the following complications may arise:

• Severe growth retardation – irreversible if chronic deficiency persists beyond early childhood.
• Immune compromise – recurrent bacterial, viral, or fungal infections; possible sepsis.
• Neurologic damage – cognitive delays, peripheral neuropathy, and, rarely, seizures.
• Dermatologic scarring – chronic lesions can lead to hyperpigmentation or atrophic scarring.
• Secondary copper deficiency – high zinc doses can inhibit copper absorption, causing anemia and neutropenia.

When to Seek Emergency Care

References

1. Mayo Clinic. Acrodermatitis enteropathica. 2021. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. Zinc Fact Sheet. 2022. https://www.cdc.gov
3. World Health Organization. Micronutrient deficiencies. 2020. https://www.who.int
4. National Institutes of Health, Office of Dietary Supplements. Zinc – Health Professional Fact Sheet. 2020. https://ods.od.nih.gov
5. Cleveland Clinic. Acrodermatitis Enteropathica. 2023. https://my.clevelandclinic.org
6. Omim.org. Acrodermatitis Enteropathica (AE) – Gene: SLC39A4. 2022. https://www.omim.org
7. National Library of Medicine. Zinc deficiency and skin disease: a review. 2020; PMID: 32745678.